Skip to content
Sign in
European CDMOs compared · 2026 census

Viral vector and vaccine CDMOs in Europe: 32 compared (2026)

32 of the 255 contract development and manufacturing organisations in A4BEE’s European census list viral vector and vaccine manufacturing among their capabilities. The largest, with revenue over €1bn, are AGC Biologics and Fujifilm Diosynth. 9 sit between €250m and €1bn and 21 are smaller or niche.

By ownership: 9 family-owned, 6 private equity, 4 listed, 10 part of a pharma or industrial group and 3 state-owned. They are spread across 15 countries, led by Germany (6), the Netherlands (5), the United Kingdom (4), France (2) and Ireland (2). 15 of the 32 rows rest on audited reports or official company disclosures; the rest come from secondary sources or estimates.

Open these 32 in the interactive mapAll 255 European CDMOs

32 companies

Viral vector and vaccine CDMOs in Europe

CompanyCountryOwnershipSizeRevenue (as reported)ModalitiesData
AGC BiologicsCopenhagen site expanded to 16,000 L single-use; broad multi-modality platform.Copenhagen, DenmarkPart of a pharma or industrial groupAGC Inc.Tier 1~US$1.2 bn (global)Monoclonal antibody, Microbial and protein, mRNA and LNP, Viral vector and vaccine, Cell and gene therapymedium
Fujifilm Diosynth~US$8 bn global capex; Hillerød (DK) site runs 12 bioreactors.Billingham, United KingdomPart of a pharma or industrial groupFujifilmTier 1~US$2.0 bn (global)Biologics and biosimilars, Monoclonal antibody, Viral vector and vaccine, Cell and gene therapymedium
BiovetaLargest Czech veterinary immunobiological/pharma maker; dedicated contract-manufacturing function (vaccines, antisera, sterile forms). Primarily veterinary.Ivanovice na Hané, CzechiaState-ownedCzech state (majority)Tier 2not disclosedBiologics and biosimilars, Viral vector and vaccine, Sterile fill-finishmedium
ExotheraViral-vector and nucleic-acid CDMO; Univercells subsidiary. First CDMO with access to Quantoom's continuous-RNA Nfinity platform.Jumet, BelgiumPart of a pharma or industrial groupUnivercellsTier 2not disclosedViral vector and vaccine, mRNA and LNP, Cell and gene therapyhigh
FinVectorcGMP viral-vector (adenoviral) gene-therapy manufacturer, FDA-approved. Now Ferring-owned and its new plant is dedicated to parent's own product — reads more captive than open CDMO.Kuopio, FinlandPart of a pharma or industrial groupFerringTier 2not disclosedViral vector and vaccine, Cell and gene therapylow
IDT BiologikaViral vaccine/vector + oncolytic virus specialist with mRNA fill-finish.Dessau-Roßlau, GermanyPart of a pharma or industrial groupSK bioscienceTier 2n/dViral vector and vaccine, Sterile fill-finish, mRNA and LNPmedium
Merck KGaA CDMOLife-Science CDMO arm covering biologics, ADC/HPAPI, viral vectors and LNP (via Exelead).Darmstadt, GermanyListedE. Merck KGTier 2not disclosedMonoclonal antibody, Biologics and biosimilars, Antibody-drug conjugate (ADC), Viral vector and vaccine, mRNA and LNPmedium
NorthX BiologicsBiologics CDMO built on the former Cobra Biologics Matfors site; Swedish national innovation hub for ATMPs.Matfors, SwedenPrivate equityFlerie InvestTier 2not disclosedMicrobial and protein, Biologics and biosimilars, mRNA and LNP, Viral vector and vaccine, Cell and gene therapy, Monoclonal antibody, Sterile fill-finishlow
RecipharmStockholm, SwedenPrivate equityEQTTier 2€827 m (2024)Sterile fill-finish, Oral solid dose, Biologics and biosimilars, mRNA and LNP, Viral vector and vaccinehigh
VibalogicsSpecialist virus/viral-vector and oncolytic-virus CDMO; PE-backed. German HQ with a US site added later.Cuxhaven, GermanyPrivate equityAmpersand Capital PartnersTier 2not disclosedViral vector and vaccine, Cell and gene therapyhigh
Viralgen Vector CoreOne of Europe's largest dedicated AAV gene-therapy vector CDMOs; founded 2017 as an AskBio subsidiary, now within Bayer.San Sebastián, SpainPart of a pharma or industrial groupBayer (AskBio)Tier 2not disclosedViral vector and vaccine, Cell and gene therapyhigh
3PBIOVIANMerger of 3P Biopharmaceuticals (Spain) + Biovian (Finland).Noáin, SpainPrivate equityKeensightTier 3~US$81 mMicrobial and protein, Viral vector and vaccine, Cell and gene therapymedium
ABL EuropeViral-vector CDMO (adeno, lenti, AAV, pox/MVA). Acquired by Oxford Biomedica in 2024.Lyon, FranceListedOxford BiomedicaTier 3not disclosedViral vector and vaccine, Cell and gene therapyhigh
APC / VLE TherapeuticsIrish-founded (UCD spinout). APC = process-dev/CMC; sister VLE runs the GMP 'factory of the future' — the group has genuine manufacturing.Dublin, IrelandFamily-ownedTier 3not disclosedSmall-molecule API, Biologics and biosimilars, Viral vector and vaccine, mRNA and LNPhigh
Batavia BiosciencesBiologics CDMO: viral vaccines/vectors, oncolytic viruses, proteins/antibodies; proprietary yield platforms. Owned by CJ (2021).Leiden, NetherlandsPart of a pharma or industrial groupCJ CheilJedangTier 3not disclosedBiologics and biosimilars, Viral vector and vaccine, Monoclonal antibodyhigh
Bilthoven BiologicalsVaccine CDMO (inactivated polio, viral-vector/Vero platforms; also mAbs). Owned by Serum Institute of India.Bilthoven, NetherlandsFamily-ownedSerum Institute of IndiaTier 3not disclosedViral vector and vaccine, Biologics and biosimilars, Monoclonal antibodyhigh
eXmoor PharmaIndependent full-service cell & gene therapy CDMO + CMC consultancy.Bristol, United KingdomPrivate equityMVM PartnersTier 3not disclosedCell and gene therapy, Viral vector and vaccine, Biologics and biosimilarsmedium
GenIbet BiopharmaceuticalsBiologics CDMO: microbial, cell culture, viral process dev + cGMP manufacture plus fill-finish. Made mRNA material for Moderna.Oeiras, PortugalPart of a pharma or industrial groupRecipharmTier 3not disclosedBiologics and biosimilars, Microbial and protein, Viral vector and vaccine, Cell and gene therapy, mRNA and LNP, Sterile fill-finishhigh
HALIXMammalian biologics CDMO: viral vectors, vaccines, recombinant proteins (1,000L SUB). Made AstraZeneca's COVID vaccine.Leiden, NetherlandsFamily-ownedDroege GroupTier 3not disclosedViral vector and vaccine, Biologics and biosimilars, Monoclonal antibodyhigh
HiTech HealthFirst Irish company licensed to contract-manufacture cell & gene therapies. End-to-end ATMP CDMO with EU/UK QP release.Galway, IrelandFamily-ownedTier 3not disclosedCell and gene therapy, Viral vector and vaccine, Biologics and biosimilarshigh
IntravaccVaccine CDMO for infectious-disease/therapeutic vaccines, PoC to Phase I/II. State-owned; sale announced.Bilthoven, NetherlandsState-ownedDutch StateTier 3not disclosedViral vector and vaccine, Biologics and biosimilars, Microbial and proteinhigh
Miltenyi BioindustryCDMO division of Miltenyi Biotec for lentiviral vectors and cell/gene therapies (supplied LVV for Adaptimmune TECELRA).Bergisch Gladbach, GermanyFamily-ownedMiltenyi BiotecTier 3not disclosedCell and gene therapy, Viral vector and vaccinelow
NecstGenNon-profit cell & gene therapy CDMO and centre of excellence in a purpose-built Leiden GMP facility; genuine third-party CGT manufacturing.Leiden, NetherlandsState-ownedTier 3not disclosedCell and gene therapy, Viral vector and vaccinemedium
Northway BiotechCEE cost-competitive biologics CDMO scaling to 5,000 L stainless steel.Vilnius, LithuaniaFamily-ownedTier 3n/dMonoclonal antibody, Microbial and protein, Biologics and biosimilars, Sterile fill-finish, Viral vector and vaccine, Cell and gene therapymedium
Oxford BiomedicaLSE-listed pure-play viral-vector / cell & gene therapy CDMO (lentiviral, AAV, adenoviral).Oxford, United KingdomListedTier 3£128.8 m (FY2024)Viral vector and vaccine, Cell and gene therapy, Biologics and biosimilars, mRNA and LNPhigh
Polymun ScientificFamily-owned biopharma/liposome-LNP CDMO; scaled the LNP process for the BioNTech/Pfizer Comirnaty vaccine.Klosterneuburg, AustriaFamily-ownedTier 3not disclosedBiologics and biosimilars, mRNA and LNP, Viral vector and vaccinehigh
ProBioGenIndependent biologics CDMO (proteins/antibodies, viral vectors, vaccines); Charité spin-off, founded 1994.Berlin, GermanyFamily-ownedTier 3not disclosedMonoclonal antibody, Biologics and biosimilars, Viral vector and vaccinemedium
Synthaverse (Biomed-Lublin)BCG vaccines + immunoglobulins + probiotics.Lublin, PolandListedTier 3~US$14 m est.Viral vector and vaccine, Biologics and biosimilarsmedium
TouchlightCDMO making enzymatic 'doggybone DNA' (dbDNA) as template for mRNA/viral-vector/genetic medicines. First synthetic-DNA maker with MHRA GMP API cert.London, United KingdomPrivate equityTier 3not disclosedCell and gene therapy, mRNA and LNP, Viral vector and vaccinemedium
Wacker BiotechHalle mRNA competence centre; microbial proteins + pDNA up to 1,500 L fermentation.Munich, GermanyPart of a pharma or industrial groupWacker ChemieTier 3n/dMicrobial and protein, mRNA and LNP, Viral vector and vaccinelow
Wellgem BiopharmaBiologics contract dev/manufacturing: mammalian + microbial cell-line/process dev, cGMP cell banking, Phase II pilot facility. Newer entrant.Vilnius, LithuaniaFamily-ownedTier 3not disclosedBiologics and biosimilars, Monoclonal antibody, Microbial and protein, Viral vector and vaccine, Cell and gene therapymedium
YposkesiCell & gene therapy CDMO (AAV + lentiviral vectors). Spun out of Genethon; SK pharmteco majority.Corbeil-Essonnes, FrancePart of a pharma or industrial groupSK pharmtecoTier 3not disclosedCell and gene therapy, Viral vector and vaccinehigh

Size: Tier 1 (revenue over €1bn) · Tier 2 (€250m–€1bn) · Tier 3 (under €250m or niche).

Revenue, staff and site figures are as reported and mix audited accounts with commercial estimates, which are often wrong for private companies. Each row carries a confidence mark; verify a figure before quoting it.

Browse the census

Other European CDMO lists